Article | Published:

The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma

Nature Cell Biology volume 16, pages 255267 (2014) | Download Citation

Abstract

Pancreatic ductal adenocarcinoma (PDA) develops through distinct precursor lesions, including pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasia (IPMN). However, genetic features resulting in IPMN-associated PDA (IPMN–PDA) versus PanIN-associated PDA (PanIN-PDA) are largely unknown. Here we find that loss of Brg1, a core subunit of SWI/SNF chromatin remodelling complexes, cooperates with oncogenic Kras to form cystic neoplastic lesions that resemble human IPMN and progress to PDA. Although Brg1-null IPMN–PDA develops rapidly, it possesses a distinct transcriptional profile compared with PanIN-PDA driven by mutant Kras and hemizygous p53 deletion. IPMN–PDA also is less lethal, mirroring prognostic trends in PDA patients. In addition, Brg1 deletion inhibits Kras-dependent PanIN development from adult acinar cells, but promotes Kras-driven preneoplastic transformation in adult duct cells. Therefore, this study implicates Brg1 as a determinant of context-dependent Kras-driven pancreatic tumorigenesis and suggests that chromatin remodelling may underlie the development of distinct PDA subsets.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Accessions

Primary accessions

Gene Expression Omnibus

References

  1. 1.

    , , & Cystic precursors to invasive pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 8, 141–150 (2011).

  2. 2.

    et al. Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas. Ann. Surg. 255, 326–333 (2012).

  3. 3.

    et al. Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas. Ann. Surg. 251, 470–476 (2010).

  4. 4.

    et al. Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut 60, 1712–1720 (2011).

  5. 5.

    & Intraductal papillary mucinous neoplasm. Hum. Pathol. 43, 1–16 (2012).

  6. 6.

    et al. Epithelial tissues have varying degrees of susceptibility to Kras(G12D)-initiated tumorigenesis in a mouse model. PLoS One 6, e16786 (2011).

  7. 7.

    Cells of origin in cancer. Nature 469, 314–322 (2011).

  8. 8.

    et al. Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc Natl Acad. Sci. USA 105, 18913–18918 (2008).

  9. 9.

    et al. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell 22, 737–750 (2012).

  10. 10.

    , & KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat. Rev. Cancer 10, 683–695 (2010).

  11. 11.

    , , & Nr5a2 maintains acinar cell differentiation and constrains oncogenic Kras-mediated pancreatic neoplastic initiation. Gut (2013)10.1136/gutjnl-2012-304287

  12. 12.

    & Epigenetics and cancer without genomic instability. Cell Cycle 8, 23–26 (2009).

  13. 13.

    & SWI/SNF nucleosome remodellers and cancer. Nat. Rev. Cancer 11, 481–492 (2011).

  14. 14.

    & Involvement of the chromatin-remodelling factor BRG1/SMARCA4 in human cancer. Epigenetics 3, 64–68 (2008).

  15. 15.

    et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394, 203–206 (1998).

  16. 16.

    et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539–542 (2011).

  17. 17.

    et al. Inactivating mutations of the chromatin remodelling gene ARID2 in hepatocellular carcinoma. Nat. Genet. 43, 828–829 (2011).

  18. 18.

    et al. Frequent mutations of chromatin remodelling genes in transitional cell carcinoma of the bladder. Nat. Genet. 43, 875–878 (2011).

  19. 19.

    et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med. 363, 1532–1543 (2010).

  20. 20.

    et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399–405 (2012).

  21. 21.

    , , & Highly penetrant, rapid tumorigenesis through conditional inversion of the tumour suppressor gene Snf5. Cancer Cell 2, 415–425 (2002).

  22. 22.

    , , , & Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumours in mice. Proc Natl Acad. Sci. USA 97, 13796–13800 (2000).

  23. 23.

    , , , & Targeted knockout of BRG1 potentiates lung cancer development. Cancer Res. 68, 3689–3696 (2008).

  24. 24.

    et al. Core signalling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801–1806 (2008).

  25. 25.

    et al. Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumour suppressive complex in pancreatic cancer. Proc Natl Acad. Sci. USA 109E, 252–259 (2012).

  26. 26.

    et al. Loss of expression of the SWI/SNF chromatin remodelling subunit BRG1/SMARCA4 is frequently observed in intraductal papillary mucinous neoplasms of the pancreas. Hum. Pathol. 43, 585–591 (2012).

  27. 27.

    , , & SNF2β-BRG1 is essential for the viability of F9 murine embryonal carcinoma cells. Mol. Cell Biol. 17, 5976–5986 (1997).

  28. 28.

    et al. The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. Nat. Genet. 32, 128–134 (2002).

  29. 29.

    , , , & Stabilization of β-catenin impacts pancreas growth. Development 133, 2023–2032 (2006).

  30. 30.

    et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad. Sci. USA 103, 5947–5952 (2006).

  31. 31.

    et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437–450 (2003).

  32. 32.

    et al. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 11, 229–243 (2007).

  33. 33.

    et al. Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. Cancer Cell 12, 266–279 (2007).

  34. 34.

    , , , & β-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice. J. Clin. Invest. 120, 508–520 (2010).

  35. 35.

    et al. Evaluation of SOX9 expression in pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasm. Pancreas 42, 488–493 (2012).

  36. 36.

    et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 19, 441–455 (2011).

  37. 37.

    et al. Stat3/Socs3 activation by IL-6 transsignalling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19, 456–469 (2011).

  38. 38.

    et al. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res. 71, 5020–5029 (2011).

  39. 39.

    et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 17, 3112–3126 (2003).

  40. 40.

    et al. LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology 139, 586–597 (2010).

  41. 41.

    et al. Gamma-aminobutyric acid (GABA) stimulates pancreatic cancer growth through overexpressing GABAA receptor pi subunit. Cancer Res. 67, 9704–9712 (2007).

  42. 42.

    & Roles of HMGA proteins in cancer. Nat. Rev. Cancer 7, 899–910 (2007).

  43. 43.

    et al. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 473, 101–104 (2011).

  44. 44.

    et al. HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph node metastasis in pancreatic adenocarcinoma. Histopathology 60, 397–404 (2012).

  45. 45.

    et al. Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression. Dev. Cell 22, 131–145 (2012).

  46. 46.

    et al. Expression of METH-1 and METH-2 in pancreatic cancer. Clin Cancer Res. 7, 3437–3443 (2001).

  47. 47.

    et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci. Trans. Med. 3, 92ra66 (2011).

  48. 48.

    et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc. Nat. Acad. Sci. USA 108, 21188–21193 (2011).

  49. 49.

    et al. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci. Rep. 1, 161 (2011).

  50. 50.

    et al. Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut 62, 1024–1033 (2013).

  51. 51.

    et al. Spatiotemporal patterns of multipotentiality in Ptf1a-expressing cells during pancreas organogenesis and injury-induced facultative restoration. Development 140, 751–764 (2013).

  52. 52.

    et al. Pancreatic exocrine duct cells give rise to insulin-producing β cells during embryogenesis but not after birth. Dev. Cell 17, 849–860 (2009).

  53. 53.

    et al. Expression of p270 (ARID1A), a component of human SWI/SNF complexes, in human tumours. Int. J. Cancer 112, 636–642 (2004).

  54. 54.

    , & BRG1 controls the activity of the retinoblastoma protein via regulation of p21CIP1/WAF1/SDI. Mol. Cell Biol. 24, 1188–1199 (2004).

  55. 55.

    , & ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodelling, is a tumour suppressor in gynecologic cancers. Cancer Res. 71, 6718–6727 (2011).

  56. 56.

    , & Role for BRG1 in cell cycle control and tumour suppression. Mol. Cell Biol. 24, 362–376 (2004).

  57. 57.

    , , & SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus. Mol. Cell Biol. 28, 3457–3464 (2008).

  58. 58.

    et al. SWI/SNF deficiency results in aberrant chromatin organization, mitotic failure, and diminished proliferative capacity. Mol. Biol. Cell 20, 3192–3199 (2009).

  59. 59.

    , & TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105–1111 (2009).

  60. 60.

    et al. The human genome browser at UCSC. Genome Res. 12, 996–1006 (2002).

  61. 61.

    et al. The sequence alignment/map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).

Download references

Acknowledgements

We thank C. Wright for sharing Ptf1a–Cre and Ptf1a–CreER mice, D. Tuveson for KrasG12D mice, and P. Chambon and D. Reisman for Brg1flox mice, respectively. We thank C. Austin and D. Ngow for tissue processing and excellent technical assistance and all M.H. laboratory members for helpful discussion. Work in M.H.’s laboratory was supported by a grant from the NIH (CA112537). G.v.F. was supported by a post-doctoral Research Fellowship from the Deutsche Forschungsgemeinschaft (DFG, FI 1719/1-1) and a Klein Family Foundation Fellowship. A.F. was supported by a post-doctoral Research Fellowship from the Japan Society for the Promotion of Science, a Fellowship from the US National Pancreas Foundation, and a Fellowship from the Kato Memorial Biosciences Foundation. M.E.L. was supported by CIRM training grant TG2 01153. W.F.M., A.B. and K.J.H. were supported by a grant from the NIH (CA149548). Image acquisition was supported by the imaging core of the UCSF Diabetes and Endocrinology Research Center (DERC) NIH grant P30DK63720.

Author information

Author notes

    • Guido von Figura
    • , Akihisa Fukuda
    • , Nilotpal Roy
    •  & Muluye E. Liku

    These authors contributed equally to this work.

Affiliations

  1. Diabetes Center, Department of Medicine, University of California, San Francisco, 513 Parnassus Avenue, HSW 1116, Box 0540 San Francisco, California 94143, USA

    • Guido von Figura
    • , Akihisa Fukuda
    • , Nilotpal Roy
    • , Muluye E. Liku
    • , John P. Morris IV
    • , Holger A. Russ
    •  & Matthias Hebrok
  2. II. Medizinische Klinik, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany

    • Guido von Figura
  3. Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan

    • Akihisa Fukuda
  4. Department of Pathology, University of California, San Francisco, San Francisco, California 94143, USA

    • Grace E. Kim
  5. Department of Surgery

    • Matthew A. Firpo
    •  & Sean J. Mulvihill
  6. Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84115, USA

    • Matthew A. Firpo
    •  & Sean J. Mulvihill
  7. Department of Pathology, University of California, Los Angeles, California 90095, USA

    • David W. Dawson
  8. Department of Medicine, Imperial College London, W12 ONN London, UK

    • Jorge Ferrer
  9. Department of Microbiology & Molecular Genetics, University of California, Irvine, California 92697, USA

    • William F. Mueller
    • , Anke Busch
    •  & Klemens J. Hertel

Authors

  1. Search for Guido von Figura in:

  2. Search for Akihisa Fukuda in:

  3. Search for Nilotpal Roy in:

  4. Search for Muluye E. Liku in:

  5. Search for John P. Morris IV in:

  6. Search for Grace E. Kim in:

  7. Search for Holger A. Russ in:

  8. Search for Matthew A. Firpo in:

  9. Search for Sean J. Mulvihill in:

  10. Search for David W. Dawson in:

  11. Search for Jorge Ferrer in:

  12. Search for William F. Mueller in:

  13. Search for Anke Busch in:

  14. Search for Klemens J. Hertel in:

  15. Search for Matthias Hebrok in:

Contributions

G.V.F., A.F., N.R. and M.E.L. contributed to equal parts. G.V.F., A.F., N.R. and M.E.L. carried out all experiments and were involved together with M.H. in design and analysis of the experiments. G.V.F., A.F., N.R., M.E.L. and M.H. drafted the manuscript. J.P.M.I.V. generated cell lines, contributed to the survival analysis, was involved in experimental analysis, and critically reviewed the manuscript. G.E.K. performed the histopathological analysis including IPMN and tumour identification and tumour grading. H.R. performed quantification of tumour proliferation. J.F. generated the HNF1b–CreERT2 mice. D.W.D. analysed Brg1 expression on human samples. M.A.F., S.J.M. and J.F. provided intellectual contribution to this study. M.F.W., A.B. and K.J.H. carried out deep sequencing analyses. M.H. conceived the study.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Matthias Hebrok.

Integrated supplementary information

Supplementary information

PDF files

  1. 1.

    Supplementary Information

    Supplementary Information

Excel files

  1. 1.

    Supplementary Table 1

    Supplementary Information

  2. 2.

    Supplementary able 2

    Supplementary Information

  3. 3.

    Supplementary Table 3

    Supplementary Information

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/ncb2916

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing